SC decision on Novartis to benefit poor patients: Pharma cos

Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options".

Supreme Court rejects Novartis cancer drug Glivec patent plea

Glivec, used in treating chronic myeloid leukemia and some other cancers, costs a patient about Rs 1.2 lakh/month, much higher than Rs 8,000 which is the price of the generic drug.

SC again asks Novartis to cut cancer drug price

The Supreme Court Wednesday once again asked pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate.

SC again asks Novartis to cut cancer drug price

The Supreme Court Wednesday once again asked pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate.

Novartis tells SC it has right to patent its cancer drug

The Supreme Court today asked Swiss pharma giant Novartis AG whether it should not sell its anti-cancer drug for Rs 5 each to benefit common man.

Novartis tells SC it has right to patent its cancer drug

The Supreme Court today asked Swiss pharma giant Novartis AG whether it should not sell its anti-cancer drug for Rs 5 each to benefit common man.